STOCK TITAN
  1. Home
  2. News
  3. PHVS

Pharvaris NV - PHVS STOCK NEWS

Welcome to our dedicated news page for Pharvaris NV (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris NV.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pharvaris NV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pharvaris NV's position in the market.

News
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) provided business updates and outlined its strategic priorities for 2024. The company demonstrated deucrictibant’s potential for the prevention and treatment of HAE attacks. They are operating from a strong financial position and anticipate an important execution year with the initiation of RAPIDe-3 and the submission of nonclinical study results to the FDA. They are also preparing to initiate the global pivotal study, CHAPTER-3, for the prophylaxis against HAE attacks. The company closed a $300 million underwritten offering, extending their cash runway for at least two years. Jochen Knolle, Ph.D., co-founder of Pharvaris, is transitioning to strategic advisor to the CEO and Executive Committee.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
none
-
News
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) presented positive results from the RAPIDe-1 Phase 2 trial of deucrictibant capsules for the on-demand treatment of hereditary angioedema (HAE) attacks at the Global Allergy and Asthma Excellence Network (GA²LEN) UCARE Conference. The results showed rapid reduction in time to symptom relief and resolution of attacks, reduced use of rescue medication, and well-tolerated capsules at all dose levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
Rhea-AI Summary
Pharvaris N.V. (PHVS) announced the pricing of an underwritten offering of 11,125,000 ordinary shares at $24.00 per share, and pre-funded warrants to purchase 1,375,000 ordinary shares at $23.99 per pre-funded warrant, expected to generate approximately $300 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.14%
Tags
offering
News
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) announced positive top-line data from the CHAPTER-1 Phase 2 clinical study, with deucrictibant demonstrating statistically significant results as an oral preventative treatment for hereditary angioedema (HAE). The primary endpoint was met, showing an 84.5% reduction in monthly attack rate compared to placebo. Deucrictibant was well-tolerated, and secondary endpoints also demonstrated clinically meaningful improvement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.14%
Tags
clinical trial
-
News
Pharvaris to Present at the GA²LEN UCARE Conference 2023
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) announced the acceptance of one abstract for oral presentation and two abstracts for poster presentation at the GA²LEN UCARE Conference 2023. The company is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Presentation details include the RAPIDe-1 Phase2 Trial Results, Symptom Relief Definitions in HAE, and Early-Onset Response to Treatment of Hereditary Angioedema Attacks with Deucrictibant. Pharvaris is a bronze level sponsor of the conference, and the presentation slides and posters will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
conferences
-
News
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) announces the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer. Dr. Abele brings over 20 years of experience in process development, API supply chain, CMC activities, GMP manufacturing, and people leadership. His role will encompass chemistry, manufacturing, and controls activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development. This appointment comes at a transformative time for Pharvaris as they prepare for Phase 3 studies and commercialization, with Dr. Abele's expertise expected to be instrumental in setting up sustainable production strategies and agile expert teams for the development of deucrictibant, a potential game-changer in the treatment of hereditary angioedema (HAE).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.49%
Tags
management
News
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) presented two ePosters at the ACAAI 2023 Annual Scientific Meeting, highlighting the positive results of the phase 2 RAPIDe-1 trial for PHVS416 in reducing time to end of progression of hereditary angioedema attacks' manifestations. The presentation also included real-world data from the Adelphi HAE Wave II Disease Specific Program, indicating the potential of PHVS416 for on-demand treatment of HAE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
clinical trial
-
News
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Pharvaris, a clinical-stage company developing oral bradykinin-B2-receptor antagonists for hereditary angioedema (HAE), reported financial results for Q3 2023. The company anticipates initiating a global Phase 3 clinical study in 1H 2024 and resolving the U.S. clinical hold on deucrictibant for HAE prophylaxis. Top-line data from the Phase 2 CHAPTER-1 study is expected by YE 2023. Pharvaris had cash and cash equivalents of €158 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
earnings
-
News
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
Rhea-AI Summary
Pharvaris, a clinical-stage company developing oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE) attacks, announced the acceptance of two abstracts for ePoster presentation at the ACAAI 2023 Annual Scientific Meeting. The presentations will focus on reducing the time to end of progression of HAE attacks' manifestations and reasons not to treat HAE attacks and satisfaction for on-demand treatment. The ePosters will be available on the Pharvaris website on November 9.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
conferences
News
Pharvaris To Present at the APAAACI 2023 International Conference
Rhea-AI Summary
Pharvaris announces acceptance of abstract oral presentation at APAAACI 2023 International Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences
Stock PHVS logo
Pharvaris NV

Nasdaq:PHVS

PHVS Rankings

#2315 Ranked by Market Cap
#18 Ranked by Stock Gains
N/A Ranked by Dividends

PHVS Stock Data

1.18B
22.01M
6.05%
83.23%
0.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Netherlands
Leiden

About PHVS

pharvaris is a preclinical stage company focused on bringing an oral bradykinin b2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (hae) and other b2 receptor-mediated indications. the company reunites the core team responsible for the discovery and approval of the hae treatment icatibant. with novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.